Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Final results from the UKALL60+ trial

In this video, Bela Wrench, MBBS, MD (res), MRCP, FRCPath, Barts Cancer Institute, London, UK, shares some insights into the rationale and final results of the UKALL60+ trial (NCT01616238), which aimed to evaluate whether there is a benefit to intensifying treatment in older adults with acute lymphoblastic leukemia (ALL). Dr Wrench first explains the various treatment arms in this study, and then goes on to highlight the results, including overall survival (OS), rates of measurable residual disease (MRD) negativity, and toxicities observed. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Pfizer: Membership on an entity’s Board of Directors or advisory committees.